WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 318076
Description: Isradipine is a calcium channel blocker of the dihydropyridine class. It is usually prescribed for the treatment of high blood pressure in order to reduce the risk of stroke and heart attack. More recent research in animal models suggests that isradipine may have potential uses for treating Parkinson's disease.
MedKoo Cat#: 318076
Chemical Formula: C19H21N3O5
Exact Mass: 371.1481
Molecular Weight: 371.3871
Elemental Analysis: C, 61.45; H, 5.70; N, 11.31; O, 21.54
Synonym: Isradipine, DynaCirc, Prescal, Lomir, PN-200-110, PN-205-033, PN-205-034
IUPAC/Chemical Name: 3-isopropyl 5-methyl 4-(benzo[c][1,2,5]oxadiazol-4-yl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate
InChi Key: HMJIYCCIJYRONP-UHFFFAOYSA-N
InChi Code: InChI=1S/C19H21N3O5/c1-9(2)26-19(24)15-11(4)20-10(3)14(18(23)25-5)16(15)12-7-6-8-13-17(12)22-27-21-13/h6-9,16,20H,1-5H3
SMILES Code: CC1=C(C(OC)=O)C(C2=CC=CC3=NON=C32)C(C(OC(C)C)=O)=C(C)N1
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO, not in water
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
The following data is based on the product molecular weight 371.3871 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
1: Anekonda TS, Quinn JF. Calcium channel blocking as a therapeutic strategy for Alzheimer's disease: the case for isradipine. Biochim Biophys Acta. 2011 Dec;1812(12):1584-90. doi: 10.1016/j.bbadis.2011.08.013. Epub 2011 Sep 8. Review. PubMed PMID: 21925266; PubMed Central PMCID: PMC3275089.
2: Hansson L. How to study the role of hypertension in atherosclerosis. Lessons from MIDAS. Multicentre Isradipine Diuretic Atherosclerosis Study. Blood Press Suppl. 1996;4:16-9. Review. PubMed PMID: 8973777.
3: Panuccio D, Trabatti MR, Bernardini A, Capone A. [Metabolic tolerance of isradipine. Evaluation after three months of therapy]. Clin Ter. 1995 Nov;146(11):729-36. Review. Italian. PubMed PMID: 8720349.
4: Blecker D. Antihypertensive therapy with isradipine in patients with special safety concerns. Angiology. 1994 Dec;45(12):997-1008. Review. PubMed PMID: 7985835.
5: Frishman WH. Calcium-channel entry blocker therapy for hypertensive patients with concomitant renal impairment: a focus on isradipine. J Clin Pharmacol. 1994 Dec;34(12):1164-72. Review. PubMed PMID: 7738211.
6: Walton T, Symes LR. Felodipine and isradipine: new calcium-channel-blocking agents for the treatment of hypertension. Clin Pharm. 1993 Apr;12(4):261-75. Review. PubMed PMID: 8458178.
7: Feneck RO, Underwood SM, Walesby RK. Isradipine and the coronary circulation. Acta Anaesthesiol Scand Suppl. 1993;99:38-42. Review. PubMed PMID: 8480505.
8: Hansson L. Isradipine: a profile in essential hypertension. Acta Anaesthesiol Scand Suppl. 1993;99:26-8. Review. PubMed PMID: 8480503.
9: Marty J. Role of isradipine and other antihypertensive agents in the treatment of peri- and postoperative hypertension. Acta Anaesthesiol Scand Suppl. 1993;99:53-5. Review. PubMed PMID: 8097608.
10: Man in't Veld AJ. The place of isradipine in the treatment of hypertension. Am J Hypertens. 1991 Feb;4(2 Pt 2):96S-102S. Review. PubMed PMID: 1827026.
11: Miller H. Isradipine: overall clinical experience in hypertension in the United States. Am J Hypertens. 1991 Feb;4(2 Pt 2):135S-139S. Review. PubMed PMID: 1827004.
12: Vidt DG. Isradipine in the treatment of hypertension: a clinical profile. Cleve Clin J Med. 1990 Nov-Dec;57(8):677-84. Review. PubMed PMID: 2147874.
13: Fitton A, Benfield P. Isradipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cardiovascular disease. Drugs. 1990 Jul;40(1):31-74. Review. PubMed PMID: 2143980.
14: Sauter A, Rudin M. Experimental studies with isradipine in stroke. Drugs. 1990;40 Suppl 2:44-51. Review. PubMed PMID: 2150641.
15: Rüegg UT, Hof RP. Pharmacology of the calcium antagonist isradipine. Drugs. 1990;40 Suppl 2:3-9. Review. PubMed PMID: 2150637.
16: Hansson L. Isradipine in hypertension. Drugs. 1990;40 Suppl 2:10-4. Review. PubMed PMID: 2150633.
17: Dahlöf B. Cardiovascular effects of isradipine (Lomir) with special emphasis on haemodynamics and antihypertensive efficacy. A review. Cor Vasa. 1990;32(2 Suppl 1):23-34. Review. PubMed PMID: 2143458.
18: Brogden RN, Sorkin EM. Isradipine. An update of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the treatment of mild to moderate hypertension. Drugs. 1995 Apr;49(4):618-49. Review. PubMed PMID: 7789292.
19: Bernini F, Soma MR, Corsini A, Paoletti R. Experimental and clinical effects of isradipine relevant to atherosclerosis. Am J Hypertens. 1994 Jul;7(7 Pt 2):30S-34S. Review. PubMed PMID: 7946176.
20: Hirschberger R. [Pharmacokinetics and -dynamics of retard formation of isradipine. Summary of studies]. Fortschr Med. 1993 Oct 30;111(30):481-4. Review. German. PubMed PMID: 8258429.